Kanada - franska - Health Canada

jubilant draximage inc. dba jubilant radiopharma - acide médronique - poudre pour solution - 10mg - acide médronique 10mg - roentgenography

Kanada - franska - Health Canada

calgary radiopharmaceutical centre / alberta health services - acide médronique - solution - 15mg - acide médronique 15mg - roentgenography

Kanada - franska - Health Canada

edmonton radiopharmaceutical centre (alberta health services) - acide médronique - trousse - 10mg - acide médronique 10mg - roentgenography

Kanada - franska - Health Canada

edmonton radiopharmaceutical centre (alberta health services) - acide médronique - trousse - 20mg - acide médronique 20mg - roentgenography

Evrópusambandið - franska - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - autres médicaments du système nerveux - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Kanada - franska - Health Canada

grifols therapeutics llc - immunnoglobuline humaine anti-hépatite b - solution - 220unité - immunnoglobuline humaine anti-hépatite b 220unité - serums

Kanada - franska - Health Canada

grifols therapeutics llc - immunnoglobuline humaine anti-hépatite b - solution - 220unité - immunnoglobuline humaine anti-hépatite b 220unité - serums

Evrópusambandið - franska - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - le myélome multiple - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. en association avec le bortézomib, la thalidomide et la dexaméthasone pour le traitement de patients adultes atteints de myélome multiple nouvellement diagnostiqué, qui sont admissibles à une greffe de cellules souches autologues. en combinaison avec le lénalidomide et de la dexaméthasone, ou le bortézomib et la dexaméthasone, pour le traitement de patients adultes atteints de myélome multiple qui ont reçu au moins un traitement antérieur. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. en tant que monothérapie pour le traitement des patients adultes en rechute et réfractaire myélome multiple, dont le traitement antérieur inclus un inhibiteur du protéasome et un agent immunomodulateur et qui ont démontré la progression de la maladie sur la dernière thérapie. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Evrópusambandið - franska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - le myélome multiple - agents antinéoplasiques - empliciti est indiqué en association avec le lénalidomide et la dexaméthasone pour le traitement du myélome multiple chez les patients adultes qui ont reçu au moins un traitement antérieur (voir les sections 4. 2 et 5.

Evrópusambandið - franska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunosuppresseurs - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.